stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Scribe Therapeutics Inc.

United States · NASDAQ: SCTX · Market cap: · P/E: · P/S:

Scribe Therapeutics designs gene-editing tools and CRISPR-based medicines to treat serious genetic and cardiometabolic diseases.

Scribe Therapeutics is a gene-editing company. It builds the molecular tools that snip, swap, and fix DNA inside living cells, then uses those tools to develop its own medicines for serious genetic diseases.

The core of its work is CRISPR, a gene-editing technology that works like a find-and-replace function for DNA. Scribe's twist is that it engineers its own versions of the editing proteins rather than using the standard ones everyone else started with. The company designs these tools to be more precise, easier to deliver into the body, and more durable as medicines. It then turns those tools into "in vivo" therapies — treatments given directly to patients so the editing happens inside their own bodies, rather than taking cells out, editing them in a lab, and putting them back. Scribe is now focused on cardiometabolic diseases, a category that includes heart-related and metabolic conditions. That is a huge patient population compared with rare genetic disorders, and it puts Scribe in a more crowded, high-stakes arena. The bet is that better editing tools can produce one-time or long-lasting treatments that beat the current standard of care, which for many of these conditions means daily pills or regular injections for life.


As a clinical-stage biotech, Scribe does not yet sell products to patients. Its money comes from investors and from partnerships — drugmakers pay for access to its editing platform and share the cost of developing medicines. The risks are the usual ones for early biotech: years of expensive testing before any approval, uncertain clinical results, and the constant need to raise more cash. If the science works, the payoff is a pipeline of medicines that could treat millions of people with a few precise edits.

Saved answer · last researched 15 Nov 2026